Clinical trials: Tumor Immunity
T-cell Lymphoma, B-Cell Lymphoma
Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer
This protocol is being submitted to consolidate, update, and expand two previously approved protocols (77-C-0066 and 82-C-0044) into a single protocol.
- Conditions
- T-cell Lymphoma, B-Cell Lymphoma, ATL, Myeloma
- Trial name
- NCT00001582
- Where
- United States
- Volunteers
- 902 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma and Vitiligo
Search for New Predictive Markers of the Immune Response in Vitiligo and Melanoma
Skin diseases can have various origins. However, a number of them are linked to an imbalance in the immune system which will lead to either an excessively strong autoimmune response or a complete lack of response against cancer…
- Trial name
- VITILIMEL (NCT04920162)
- Testing
- Biospecimen into patients who had skin diseases
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Leukaemia (Acute), Leukaemia (Chronic)
WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation
The study is not currently recruiting new subjects due to an interruption in funding from its sponsors. Efforts are under way to re-establish funding, however, the study is currently on-hold pending the outcome of these…
- Conditions
- Leukaemia (Acute), Leukaemia (Chronic), Leukaemia (Acute Myeloid), Leukaemia (Acute Lymphoblastic)
- Trial name
- WIN (NCT01334060)
- Testing
- p.DOM-WT1-37 DNA Vaccine and p.DOM-WT1-126 DNA Vaccine
- Where
- 3 sites in United Kingdom
- Volunteers
- 23 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Colorectal Cancer
Immune Response in Peripheral Blood of Patients With Colon Cancer
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that may occur in the immune system that may help kill cancer cells.
- Trial name
- NCT00900432
- Testing
- immunoenzyme technique, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- University of Arizona
Epstein-Barr Virus Infection, Infectious Mononucleosis
Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons
Background: Epstein-Barr virus (EBV) causes most cases of infectious mononucleosis (mono). Mono can cause fatigue that lasts more than 6 months, and some people can have severe complications.
- Conditions
- Epstein-Barr Virus Infection, Infectious Mononucleosis, Herpesvirus
- Trial name
- NCT05683834
- Testing
- Matrix-M1 Adjuvant, EBV gp350-Ferritin Vaccine
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Prostate Cancer
Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer
Background: Enzalutamide is a well tolerated hormone therapy that is used to treat advanced prostate cancer. It is given to help kill cancer cells and limit cancer cell growth.
- Trial name
- NCT01875250
- Testing
- PROSTVAC-F (Fowlpox)/TRICOM, PROSTVAC-V (Vaccinia)/TRICOM, Enzalutamide (Xtandi)
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Cancer, Cancer of the Endometrium
TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer
Patients with inoperable endometrial cancer have limited treatment options. PD-L1 expression is common in endometrial cancers and RT induces tumor and systemic changes that induce the immune system.
- Trial name
- NCT03955978
- Testing
- TSR-042, Brachytherapy, Endometrial biopsy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine
Lymphoma
Vaccine Therapy Following Chemotherapy & Peripheral Stem Cell Transplantation in Treating Non-Hodgkin's Lymphoma
RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response to kill cancer cells. Vaccine therapy may be an effective treatment for non-Hodgkin's lymphoma.
- Trial name
- NCT00006478
- Testing
- autologous tumor cell vaccine, keyhole limpet hemocyanin, sargramostim
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Nebraska
Cervical Cancer, Anogenital Warts
Evaluation of Long Term Immunity Following HPV Vaccination
In Fiji, cervical cancer is the second most frequent cancer and the highest cause of cancer mortality in women. In 2008/9, the Ministry of Health in Fiji accepted a donation of 110,000 doses of quadrivalent HPV vaccine, Gardasil®…
- Trial name
- NCT02276521
- Testing
- Cervarix®
- Where
- Fiji
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
Breast Adenocarcinoma, HER2-Positive Breast Carcinoma
Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer
This study gathers information from the blood cells and tumor tissue during treatment with anti-HER2 therapies, such as trastuzumab, pertuzumab, lapatinib, or neratinib, in patients with HER2 positive stage I-IV breast cancer who…
- Conditions
- Breast Adenocarcinoma, HER2-Positive Breast Carcinoma, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT04517838
- Testing
- Biospecimen Collection
- Where
- United States
- Volunteers
- 230 people
- Sponsor
- Mayo Clinic
Leukemia, Myelomonocytic, Chronic
A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML)
Enrolled subjects will receive histamine dihydrochloride (HDC; Ceplene®) and/or IL-2 (Proleukin®) subcutaneously (s.c.) twice daily (BID) in 3-week periods followed by 3- or 6 week rest periods.
- Trial name
- NCT03040401
- Testing
- Cohort 1, Ceplene® and Proleukin®, Cohort 2, Ceplene® and Proleukin®, Cohort 3, Ceplene® and Proleukin®
- Where
- 2 sites in Sweden
- Volunteers
- 15 people
- Sponsor
- Vastra Gotaland Region
Pheochromocytoma, Paraganglioma
Hereditary Pheochromocytoma Assessment of Tumour Immunologies
In this study, the investigators are examining the role of the immune system in pheochromocytoma and paraganglioma. The investigators aim to examine the differences in the immune system between people who have these tumors with…
- Trial name
- HEPHESTOS (NCT06444607)
- Testing
- Venepuncture
- Where
- Netherlands
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Epithelial Ovarian Cancer
Determining Prognostic Immune Markers in Patients With Ovarian Cancer
The IMPRoVE study is a prospective, non-interventional, explorative cohort study to determine prognostic immune markers in patients with epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer (EOC).
- Trial name
- IMPrOVE (NCT03862677)
- Testing
- No intervention
- Where
- Netherlands
- Volunteers
- 300 people
- Sponsor
- Leiden University Medical Center
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat
This phase II trial studies how well tavokinogene telseplasmid with electroporation (tavo-EP), pembrolizumab, and epacadostat work in treating patients with squamous cell carcinoma of the head and neck that cannot be removed by…
- Conditions
- Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03823131
- Testing
- ImmunoPulse, Epacadostat, Pembrolizumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Chase Heaton, MD
Melanoma Stage III or IV
Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection
Dendritic cells (DCs) are the professional antigen-presenting cells of the immune system. As such they are currently used in clinical vaccination protocols in cancer patients, and both immunological and clinical responses have…
- Trial name
- NCT00243594
- Testing
- Peptide-pulsed dendritic cells
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Radboud University Medical Center
Prostate Cancer
High Impact Training to Patients with Prostate Cancer and Bone Metastases
HIP is a randomized controlled trial. The aim is investigate the effect, safety and feasibility of brief, high-impact exercise targeting bones in patients with prostate cancer and bone metastases.
- Trial name
- HIP (NCT06259279)
- Testing
- High intensity high impact exercise intervention
- Where
- Denmark
- Volunteers
- 102 people
- Sponsor
- Copenhagen University Hospital at Herlev
Lung Cancer Stage IV
Re-induction of a Systemic Immune Response in Metastatic or Locally Recurrent Lung Cancer
Patients with metastatic non-small cell lung cancer (NSCLC) who after an initial response to immunotherapy of chemo-immunotherapy show diffuse disease progression are treated with chemotherapy, with a median PFS of about 3 months…
- Trial name
- Re-Induce 2 (NCT06024941)
- Testing
- Radiation
- Where
- Netherlands
- Sponsor
- Maastricht Radiation Oncology
Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
The PROPHETIC study is a prospective, multi-center, international clinical study aimed at developing an algorithm to predict patient outcomes.
- Conditions
- Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Unresectable Non-Small Cell Lung Cancer
- Trial name
- PROPHETIC (NCT04056247)
- Testing
- Plasma sample collection
- Where
- 41 sites in United States, Germany and 3 more
- Volunteers
- 10,000 people
- Sponsor
- OncoHost Ltd.
Hepatocellular Carcinoma, Colorectal Cancer Liver Metastasis
The Safety, Efficacy, and Immune Response of Multimodal Thermal Therapy in the Treatment of Malignant Liver Tumors
Multimodal thermal therapy (MTT), as an initiative integration of cryotherapy and radiofrequency heating, has been applied to treat various solid tumors.
- Trial name
- NCT07159048
- Testing
- Multimodal Tumor Thermal Therapy System, Radiofrequency Ablation System or Microwave Ablation System
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fudan University
Prostate Cancer
Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer
Background: Enzalutamide is a hormone therapy that is used to treat advanced prostate cancer. It is given after chemotherapy and surgery to help the body destroy the cancer cells.
- Trial name
- NCT01867333
- Testing
- PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) -F/TRICOM, PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) -V/TRICOM, Enzalutamide
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)